Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06607185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06607185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 21, 2024
Completion date
January 31, 2030
Enrollment
750 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, colorectal cancer, metastatic solid tumor, non-small cell lung cancer, pancreatic ductal adenocarcinoma